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Abstract
Purpose Temozolomide (TEM) based therapy has been
reported being effective in the treatment of metastatic
neuroendocrine neoplasms (NEN), with response rates
ranging from 30 to 70%. Among patients affected by
advanced glioblastoma or melanoma and treated with TEM,
loss of tumoral O6-methylguanine DNA methyltransferase
(MGMT) is correlated with improved survival. In NEN
patients, the role of MGMT deficiency in predicting clinical
outcomes of TEM treatment is still under debate.
Methods In this study we evaluated 95 patients with
advanced NENs undergoing treatment with TEM-based
therapy. MGMT promoter methylation status was evaluated
with two techniques: methylation specific-polymerase chain
reaction or pyrosequencing.
Results Treatment with TEM-based therapy was associated
with an overall response rate of 27.4% according to
RECIST criteria (51.8% of patients with and 17.7% without
MGMT promoter methylation). Response to therapy, pro-
gression free survival and overall survival was correlated to
MGMT status at univariate and multivariate analysis.
Methylation of MGMT promoter could be a strong pre-
dictive factor of objective response and an important
prognostic factor of a longer PFS and OS.
Conclusion According to our results, MGMT methylation
status, evaluated with methylation specific-polymerase
chain reaction or pyrosequencing, should have an impor-
tant role in patients with metastatic NENs, in order to guide
therapeutic options. These results need further confirmation
with prospective studies.
Keywords Neuroendocrine neoplasms ● Temozolomide ●
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Introduction
Neuroendocrine neoplasms (NENs) are tumors arising from
neuroendocrine cells. They are most frequently located in
the lung, the pancreas and the gastrointestinal (GI) tract.
Neuroendocrine tumors (NETs) have a reported incidence
of 2.5–5 cases/100,000 people and a prevalence of 35/
100,000 people [1]. NENs may be classified by grade (G)—
G1 defined by mitotic index < 2 mitoses/10 high power
fields (hpf) and Ki-67 ≤ 2%, G2 defined by mitotic index
2–20 mitoses/10 hpf and Ki-67 3–20%, and G3 defined by
mitotic index > 20 mitoses/10 hpf and Ki-67 > 20% [2].
Another classification takes into account the expression of
somatostatin receptors which can be targeted by somatos-
tatin analogues (SSAs) and may represent a first line sys-
temic treatment for stable or slowly progressive advanced
disease. For those tumors not expressing somatostatin
receptors and for those expressing them after progression to
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SSAs, the therapeutic landscape is rapidly evolving and
multiple treatment options are currently available. There-
fore, sequencing and tailoring the various available treat-
ments is becoming more and more challenging.
Randomized prospective studies reported the good clinical
outcome of molecular therapies targeting angiogenesis and
the mTOR pathway, such as sunitinib [3] and everolimus [4,
5], in patients with advanced progressing NENs. Although
targeted therapies are reported to frequently achieve pro-
longed progression-free survival (PFS) in patients with
pNENs, they are rarely associated with objective tumor
shrinkage [6].
Response rates ranging from 30 to 70% are reported
when TEM-based chemotherapy regimens are used in the
treatment of metastatic pNENs [7–10]. TEM is an oral
alkylating agent, whose cytotoxic activity is related to DNA
alkylation/methylation at the O6 and N7 positions of gua-
nine, resulting in DNA mismatch and tumor cell death. The
suicide enzyme O6-methylguanine DNA methyltransferase
(MGMT) repairs DNA by removing the O6-alkylguanine
adducts. High levels of MGMT, whose expression is
regulated by mean of promoter methylation, contribute to
chemoresistance by counteracting the therapeutic effect of
alkylating agents [11].
A loss of tumoral MGMT is associated with improved
survival in patients affected by advanced glioblastoma or
melanoma treated with TEM [12–14]. In NEN patients,
however, conflicting results have been reported so far [15–
20], and the role of MGMT deficiency in predicting the
clinical outcome of patients treated with TEM is still under
debate. The objective of our study was to evaluate retro-
spectively the value of MGMT status in predicting treat-
ment efficacy in a large cohort of NEN-patients treated with
TEM-based therapy.
Patients and methods
Study design and patients
A multicenter, international retrospective analysis of pro-
spective institutional database was performed. The study
included all consecutive patients with histologically proven,
locally advanced or metastatic NENs treated with TEM,
alone or in combination with capecitabine, in the partici-
pating centers (Sant’Orsola Malpighi Hospital, Bologna,
Italy; Centre Hospitalier Universitaire de Lyon, Lyon,
France; Istituto Nazionale dei Tumori, Milano, Italy; Poli-
clinico di Modena, Modena, Italy) from January 2008 to
March 2016. Inclusion criteria were: (a) histologically
proven neuroendocrine neoplasms, (b) signed informed
consent for participation in clinical research studies; (c)
complete follow-up period in one of the participating
institutions and (d) known MGMT promoter methylation
status or availability of tissue material for sequencing. The
primary end-point was to evaluate the correlation between
objective response and MGMT promoter status. The sec-
ondary end-point was to evaluate the correlation between
MGMT promoter status and both PFS and overall survival
(OS).
At baseline evaluation, all patients underwent clinical
examination, haematological, liver and kidney function
tests, a computed tomography scan (CT) and/or magnetic
resonance imaging (MRI). Patients received TEM alone or
in combination with capecitabine (CAPTEM). TEM was
administrated orally for five consecutive days every 28 days
at dose set by investigator (not standardized). In the com-
bination, capecitabine was administrated orally every
28 days at dose set by investigator (days 1–14) and TEM as
described above (days 10–14). All patients gave their
informed written consent to the chemotherapy. The treat-
ment was approved by the local Ethics Committee. Routine
blood tests were performed before each cycle of therapy as
well as during follow-up visits. The CT scan (or MRI) was
repeated every 3 months (±1 month) until disease pro-
gression according to RECIST criteria (unless clinical
conditions required shorter intervals).
Data analysis
All data were prospectively collected at the center where the
patient had been enrolled. A single computerized data sheet
was created and data regarding demographic, clinical and
pathological features were retrospectively analysed. The
histological specimens were examined by an experienced
pathologist at each center. When required, an additional
centralized revision of the tumor specimen was performed.
Tumors were classified according to the 2010 WHO clas-
sification (gastro-entero-pancreatic neuroendocrine tumors)
or 2004 WHO classification (thoracic neuroendocrine
tumors) and the ENETS grading system [2, 21]. Ki-67
proliferation index was expressed as a percentage based on
the count of Ki-67-positive cells in 2000 tumor cells in the
areas of the highest immunostaining using the MIB1 anti-
body (DBA, Milan, Italy). The tumors were evaluated
according to the RECIST criteria [22]. Objective response
rate (ORR) was defined as the proportion of patients who
achieved complete response (CR) or partial response (PR)
as better response during therapy. Predictive factors for
objective response were evaluated at univariate and multi-
variate analysis using logistic regression. Predictive factors
were expressed as odds ratio (OR) [95 % confidence
interval (CI)]. The multivariate model was designed using
the forward stepwise method after including all variables.
PFS was defined as the interval between the start of
the therapy and the time of progression of disease (PD).
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PFS was measured using the Kaplan-Meier method and the
results were compared using the log-rank test. Predictive
risk factors for PD were evaluated by univariate and mul-
tivariate analysis using the Cox proportional hazards
method. Risk factors were expressed as hazard ratios (HR)
[95% confidence interval (CI)]. The multivariate model was
designed using the forward stepwise method after including
all variables. All analyses carried out for predictive and risk
factors are listed in the tables. The distribution of the con-
tinuous variables was reported as median and interquartile
range (IQR, 25th to 75th percentiles). The comparison
between the subgroups was performed using Pearson’s chi-
square test (Fisher’s exact test was used when appropriate)
or the Mann–Whitney U test for continuous variables. The p
value was considered significant when inferior to 0.05.
Statistical analysis was performed using a dedicated soft-
ware (IBM—SPSS Statistics v. 22).
MGMT promoter methylation
MGMT promoter methylation status was evaluated using
two techniques: methylation specific-polymerase chain
reaction (MS-PCR) or pyrosequencing (PSQ), obtaining,
respectively, qualitative and quantitative information. All
samples examined contained more than 80% tumor cells.
DNA extraction from formalin-fixed, paraffin-embedded
tissue was performed after deparaffinization using a pur-
ification kit (MasterPure DNA, Epicentre, Madison, WI,
USA). Genomic DNA was modified by bisulfite conversion
(EZ DNA Methylation Gold Kit, Zymo, Irvine, CA, USA).
For MS-PCR, we used the primers and PCR conditions
described by Dong et al. [23].
Pyrosequencing was performed using the commercially
available PyroMark Q24 CpG MGMT kit (Qiagen, Hilden,
Germany) on a PyroMark Q24 System (Qiagen). Data were
analyzed and quantified with the PyroMark Q24 Software
2.0.7 (Qiagen). The mean percentage of the five CpG
methylated islands detected by the kit was used for analysis
[24, 25]. For pyrosequencing analysis, an 8% cut off was
used, accordingly to neuro-oncology clinical practice [25].
MGMT was considered methylated if methylated alleles
were more than not methylated alleles by at least 8%;
otherwise MGMT was scored as not methylated.
Results
Demographics and tumor characteristics
One hundred and four patients affected by NENs were
enrolled at the participating centers. Nine patients were
excluded at statistical analysis because TEM-based therapy
was interrupted early (median: 2 cycles, range 1–3) without
radiological evidence of progression (due to worsening of
clinical conditions in five patients and to drug-related
toxicity in four patients). The characteristics of the 95
patients are listed in Table 1. There were 52 men and 43
women with a mean age of 62 years (range 20–84 years). In
43 of the 95 patients (45.3%), the primary lesion was
located in the pancreas, in 22 (23.2%) it was in the lung,
whereas in 30 (31.6%) it was in: GI tract (21 patients),
larynx (1 patient), unknown (6 patients) or adrenal gland (2
patients). According to the 2010 WHO classification, 7
Table 1 General features of the 95 patients treated with TEM-based
therapy and according to MGMT status
Total (n=
95)
MGMT+
(n= 27)
MGMT-
(n= 68)
N % N % N % p
Sex
Male 52 54.7 17 63.0 35 51.5 0.310
Female 43 45.3 10 37.0 33 48.5
Primary Site
Pancreas 43 45.3 13 48.1 30 44.1 0.796
Lung 22 23.2 5 18.5 17 25.0
Other 30 31.6 9 33.4 21 30.9
Grade
Low grade 68 71.6 16 64.0 52 77.6 0.186
High grade 24 25.3 9 36.0 15 22.4
Not evaluable 3 3.2
Lines of therapy
First 20 21.0 4 14.8 16 23.5 0.347
Subsequent 75 78.9 23 85.2 52 76.5
Previous Chemotherapy
Yes 37 38.9 15 55.5 22 32.3 0.036
No 58 61.1 12 44.5 46 67.7
Median Ki67 13.0 16.5 12.5 0.824
IQR 6–25 7–30 4–21
Therapy
TEM alone 41 43.2 12 44.4 29 42.6 0.873
CAPTEM 54 56.8 15 55.6 39 57.4
Best Response
CR+PR 26 27.4 14 51.8 12 17.7 0.001
SD+PD 69 72.6 13 48.2 56 82.3
MGMT determination
PSQ 53 55.8 15 55.5 38 55.9 0.977
MS-PCR 42 44.2 12 44.5 30 44.1
MGMT+ MGMT promoter methylated, MGMT− MGMT promoter
not methylated, TEM temozolomide, CAPTEM capecitabine+ temo-
zolomide, CR complete response, PR partial response, SD stable
disease, PD progressive disease, PSQ pyrosequencing, MS-PCR
methylation specific-polymerase chain reaction
Bold values are statistical significance
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patients (7.4%) had a NET G1, 43 (45.3%) had a NET G2
and 20 (21.0%) had a neuroendocrine carcinoma (NEC);
according to the 2004 WHO classification, 5 (5.3%) had a
typical carcinoid of the lung, 13 (18.9%) an atypical car-
cinoid and 4 (4.2%) a large cell neuroendocrine carcinoma.
Three of the 95 patients presented with a not otherwise
specified NEN diagnosis and histological revision was not
possible due to the scarcity of the tissue samples. Con-
sidering pathological characteristics, patients were divided
in low-grade (68 patients with NET G1, NET G2, typical
and atypical carcinoids) and high grade (24 patients with
NECs and large cell lung NECs). Median Ki67 was 13.0%
(IQR: 6–25%). Tumors were metastatic in 94 patients and
locally advanced in 1 patient. Ninety-three (97.9%) patients
progressed at the time of TEM-based therapy start. TEM-
based therapy was first line treatment in 20 (21.0%) patients
and a subsequent line in 75 (78.9%). Among these latter 75
cases, 37 (38.9%) patients had been treated previously with
another chemotherapy regimen.
MGMT status
MGMT status was evaluated with PSQ in 53 (55.8%)
patients and MS-PCR in 42 (44.2%). Twenty-seven patients
(28.4%) presented a MGMT promoter methylation (MGMT
+), while 68 (71.6%) had MGMT promoter not methylated
(MGMT−). As reported in Table 1, there was no difference
in MGMT promoter methylation when considering sex,
primary site (pancreas, lung, other), grading (low and high
grade), Ki67, chemotherapy regimen (TEM alone or CAP-
TEM) and type of MGMT determination.
Treatment outcome
Patients received a median of six cycles of chemotherapy
(range 1–45). Reasons for treatment discontinuation inclu-
ded radiological tumor progression (n= 48), maximal
response or chemotherapy break (at physician’s discretion;
n= 38), unacceptable toxicity (n= 1) and patient decision
(n= 1). Seven patients were still on treatment at the time of
data analysis. All 95 patients were assessable for radio-
graphic response. When best response to therapy was
evaluated, 26 (27.4%) patients experienced PR according to
RECIST criteria, whereas 42 (44.2%) had stable disease and
27 (28.4%) experienced PD. Fourteen patients MGMT+
(51.8%) and 12 patients MGMT− promoter methylation
(17.7%; p= 0.001) achieved an objective response
(Table 1).
As reported in Table 2, CAPTEM regimen (OR: 3.43, p
= 0.019), MGMT promoter methylation (OR: 5.03, p=
0.001) and pancreatic primary site (OR: 3.85, p= 0.030)
resulted being predictive factors of objective response at
univariate analysis. Multivariate analysis confirmed the role
of CAPTEM therapy (OR: 3.87, p= 0.019) and MGMT
promoter methylation (OR: 6.53, p= 0.001).
Progression-free survival
At the time of data cut-off, 74 patients (77.9%) had PD.
Median PFS was 10 months (95% CI: 5.6–14.4 months;
Fig. 1). Significant differences in PFS were observed
according to MGMT promoter methylation with median
PFS being 21 and 8 months for MGMT+ and MGMT−,
respectively (p= 0.017, Fig. 2). Differences in PFS were
also correlated with previous chemotherapy (yes/no: 6/
17 months, p= 0.039) and objective response during
treatment (median PFS: 27 vs. 7 months; p= 0.001);
however, no statistically significant difference was observed
when correlating PFS to sex (median in male: 11 months,
female: 9 months; p= 0.881), grading (median in high
grade: 9 months, low grade: 12 months; p= 0.309), primary
site (median in pancreas: 13 months, lung: 12 months,
other: 7 months; p= 0.212), regimen (median in CAPTEM:
13 months, TEM: 7 months, p= 0.758) and line of therapy
(median in first line: 17 months, not first line: 9 months,
p= 0.336).
Risk factors for PFS were reported in Table 3. At
univariate analysis, significant risk factors were
MGMT- (HR: 1.88, p= 0.023), higher Ki67 (HR: 1.01,
p= 0.029) and previous chemotherapy (HR: 1.60,
p= 0.048). These risk factors, previously identified at uni-
variate analysis, were also confirmed at multivariate
Table 2 Predictive factors of objective response at univariate and
multivariate analysis
Univariate Multivariate
OR 95% CI P value OR 95%
CI
P value
Male gender 1.18 0.47–2.93 0.723 – – –
Primary site
Pancreas vs.
other
3.85 1.14–13.06 0.030 – – –
Lung vs. other 2.44 0.59–9.98 0.216 – – –
High grade 1.39 0.51–3.79 0.522 – – –
First line of
therapy
1.18 0.40–3.49 0.767 – – –
Previous
Chemotherapy
0.97 0.38–2.45 0.952 – – –
CAPTEM
Therapy
3.43 1.23–9.58 0.019 3.87 1.25–
11.97
0.019
MGMT+ 5.03 1.89–13.38 0.001 6.53 2.23–
19.10
0.001
MGMT+ MGMT promoter methylated, CAPTEM capecitabine+
temozolomide, OR odds ratio
Bold values are statistical significance
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analysis: MGMT- with HR: 2.62 (p= 0.003), higher Ki67
with HR: 1.02 (p= 0.019) and previous chemotherapy with
HR: 1.92 (p= 0.014). Sex, primary site, grading, che-
motherapy regimen and line of therapy were not statistically
significant.
Overall survival
A total of 46 (48.9%) out of 95 patients died during follow-
up. Median OS was 33 months (95% CI: 19.9–46.1 months;
Fig. 1b). Differences in OS were observed when stratified
according to MGMT promoter methylation with median OS
being “not reached” and 23 months for MGMT+ and
MGMT−, respectively (p= 0.057, Fig. 2b). Differences in
OS were also correlated with objective response during
therapy (median OS: 54 vs. 19 months; p= 0.001), grading
(median OS in high grade: 17 months, low grade:
35 months; p= 0.017) and previous chemotherapy (median
OS: yes/no 19/54 months; p= 0.001). However, no statis-
tically significant difference was observed when correlating
OS with sex (median in male: 33 months, female:
23 months; p= 0.971), primary site (median in pancreas:
35 months, lung: 58 months, other: 17 months; p= 0.095),
regimen (median in CAPTEM: 33 months, TEM:
34 months, p= 0.497) and line of therapy (p= 0.106). Risk
factors for OS were reported in Table 4. At multivariate
analysis MGMT− (HR: 2.87, p= 0.003), higher Ki67 (HR:
1.02, p= 0.001) and previous chemotherapy (HR: 2.87,
p= 0.003) were risk factors for poorer OS.
A
MGMT+
MGMT-p=0.017
B 
MGMT+
MGMT-
p=0.057 
Fig. 2 A. Kaplan-Meier estimates of progression-free survival a and overall survival b in 95 patients treated with TEM-based therapy according to
MGMT status. MGMT− MGMT promoter not methylated, MGMT+ MGMT promoter methylated
Fig. 1 Kaplan-Meier estimates of progression-free survival a and overall survival b in 95 patients treated with TEM-based therapy
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Discussion
In this series, we have evaluated retrospectively the predictive
value of MGMT methylation status by MS-PCR or PSQ in a
large cohort of NEN patients treated with TEM-based che-
motherapy. We observed that MGMT promoter methylation
was a strong predictive factor for objective response and an
important prognostic factor of longer PFS and OS.
It has been widely reported that MGMT status is a
powerful predictor of response to TEM for newly diagnosed
glioblastoma patients [26]. MGMT status is commonly
assessed by immunohistochemistry (IHC), MS-PCR,
quantitative MS-PCR (qMS-PCR), and/or PSQ. Immuno-
histochemistry stain for MGMT protein expression was the
easiest method to perform, but it had a lower predictive
power for PFS and OS. On the contrary, PSQ, MS-PCR,
and qMS-PCR represent the gold standard methods to
evaluate MGMT status [27]. In the last 10 years, evidences
suggesting the efficacy of TEM in metastatic NENs are
mounting [7–10, 15, 18, 19]. Therefore, the use of TEM,
either as mono- or combination therapy with capecitabine,
has been reported for the first time in the most recently
updated ENETS guidelines [28]. Nevertheless, previous
studies concerning the role of MGMT status in NENs
reported contrasting results. In two previous studies [15, 19,
29–31] no correlation was found between MGMT status
and response to TEM. In three other studies [16, 18, 20], a
predictive value was found only in the sub-group of pan-
creatic NENs. In all these series, the evaluation of MGMT
status was observed in a scarce number of cases and only in
three series MS-PCR or PSQ techniques were used
[18, 29, 30].
The primary end-point of our study was the identification
of a correlation between MGMT promoter methylation
Table 4 Risk factors of overall
survival related during follow-
up after univariate and
multivariate analysis
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Male gender 1.01 0.56–1.84 0.971 – – –
Primary site
Other vs. Lung 1.77 0.79–3.98 0.168 – – –
Other vs. Pancreas 1.99 1.02–3.87 0.042 – – –
High grade 2.16 1.12–4.15 0.021 – – –
First line of therapy 0.49 0.21–1.19 0.016 – – –
Previous Chemotherapy 2.66 1.44–4.91 0.002 2.87 1.44–5.75 0.003
CAPTEM Therapy 0.82 0.45–1.47 0.501 – – –
MGMT- 2.00 0.96–4.16 0.064 2.91 1.24–6.86 0.014
Ki67* 1.03 1.01–1.04 <0.001 1.02 1.01–1.04 0.001
MGMT− MGMT promoter not methylated, CAPTEM capecitabine+ temozolomide, HR hazard ratio
*Continuous variable
Bold values are statistical significance
Table 3 Risk factors of
progression free survival during
follow-up after univariate and
multivariate analysis
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Male gender 0.97 0.60–1.54 0.885 – – –
Primary site
Other vs. Lung 1.58 0.84–2.97 0.154 – – –
Other vs. Pancreas 1.49 0.88–2.52 0.141 – – –
High grade 1.31 0.76–2.23 0.327 – – –
First line of therapy 0.75 0.41–1.37 0.355 – – –
Previous Chemotherapy 1.60 1.01–2.54 0.048 1.92 1.14–3.22 0.014
CAPTEM Therapy 0.93 0.58–1.49 0.766 – – –
MGMT- 1.88 1.09–3.24 0.023 2.62 1.38–5.00 0.003
Ki67* 1.01 1.00–1.03 0.029 1.02 1.00–1.03 0.019
MGMT− MGMT promoter not methylated, CAPTEM capecitabine+ temozolomide, HR hazard ratio
*Continuous variable
Bold values are statistical significance
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(evaluated with MS-PCR and PSQ) and objective response
in patients treated with TEM-based therapy. Our data
strongly suggest that MGMT methylated tumors are more
sensible to TEM-based chemotherapy. In fact, we showed a
ORR of 51.8 and 17.7% in patients with or without MGMT
promoter methylation, respectively. The presence of
MGMT promoter methylation represented a strong pre-
dictive factor for response at univariate and multivariate
analysis (OR: 8.67, p< 0.001). In 2015, Walter et al.
reported the association of MGMT status (evaluated by
MSP and PSQ) and ORR in 53 patients affected by GI and
lung NENs [17]. The association of capecitabine and TEM
compared to TEM alone (OR: 4.5, p= 0.015) resulted being
a further independent factor for ORR. This data was not
previously reported and a randomized phase II study com-
paring TEM vs. CAPTEM is currently ongoing (Clin-
icalTrials.gov Identifier: NCT01824875) to prospectively
demonstrate this data. This evidence, if confirmed, could
have a strong clinical relevance in all situations in which
tumor shrinkage is needed, such as in presence of a high,
symptomatic tumor burden, or when a down-staging for
borderline surgically resectable tumors is needed to allow a
surgical approach. Our results suggest that the presence of
MGMT promoter methylation and the combination of
capecitabine and TEM could be effective to achieve a dis-
ease down-staging.
When considering the efficacy of TEM-based treatment,
we observed complete and partial response in 27.4% of
patients. Our data was similar to what had been previously
reported. In literature, ORR ranged from 20 to 70% [8, 17–
19, 30]. Walter et al. reported an ORR of 20% in a cohort of
pancreatic and GI NENs [17]. On the other hand, Cives
et al. in 2016 reported a ORR of 54% in a large cohort of
pancreatic NENs [19]. Our data was similar to what
reported by Walter and, if considering only pancreatic
NENs, we found a lower ORR (34%) compared to the data
reported by Cives. These differences could be explained
considering the different therapeutic approaches used. In
fact, Cives reported the use of a specific CAPTEM schedule
while we used TEM alone (31.9% of pancreatic NENs) or
associated with capecitabine (68.1% of pancreatic NENs) in
different and not standardized schedules.
Considering the secondary end-point, in our series we
observed a significant difference in PFS after TEM-based
therapy according to MGMT status. Median PFS was found
to be significantly longer in patients with MGMT promoter
methylation (21.0 vs. 8.0, p= 0.017). The analysis of
prognostic factors for disease progression showed that the
absence of MGMT promoter methylation increased the risk
of disease progression 2.5 times at multivariate analysis.
Our data were similar to those published by Walter et al,
reporting a 16 months’ difference in median PFS between
methylated and not methylated patients (26.0 vs.
10.8 months) [17]. Recently, Raj et al. did not report any
correlation with MGMT status nor response to alkylating
agent therapy in a cohort of 46 patients with pancreatic
NETs [30]. In this paper, PSQ was performed only in 28/56
patients and only a descriptive statistics analysis is reported.
In our series, a higher Ki67 value and previous che-
motherapy represented another independent prognostic
factors of disease progression. The role of Ki67 as a prog-
nostic factor in NENs is well known and widely demon-
strated [32–34]. No differences were found when
considering the primary site and the association between
capecitabine and TEM.
Overall survival with TEM-based therapy was sig-
nificantly longer in patients with MGMT promoter methy-
lation (not reached vs. 23 months, p= 0.057) and MGMT
status, Ki67 and previous chemotherapy were prognostic
factors for death at multivariate analysis. Walter et al.
described similar result in 2015 with a median OS of 77 and
43 months in patients with and without MGMT promoter
methylation [17]. Our results confirmed the role of MGMT
status in OS in a larger cohort of patients treated with TEM-
based therapy.
However, our results must be interpreted with some
caution due to the retrospective design of our study, due to
the use of two different technical methods to evaluate
MGMT status (PSQ and MS-PCR) and to the fact that TEM-
based therapy has been used with different schedules,
making it difficult to properly assess its role in treatment
efficacy. Prospective studies based on the assessment of
MGMT status which could confirm our results are ongoing:
an Italian phase II study testing TEM and lanreotide in
bronchial carcinoid tumors (ClinicalTrials.gov Identifier:
NCT02698410) and an American randomized phase II study
comparing TEM-capecitabine vs. TEM alone in pancreatic
NET (ClinicalTrials.gov Identifier: NCT01824875).
In conclusion, our data suggests a role of MGMT status,
evaluated with MS-PCR or PSQ, in patients treated with
TEM-based therapy. Methylation of MGMT promoter
could be considered a predictive factor for objective
response and a prognostic factor for a longer PFS and OS.
Prospective studies to confirm this evidence are required
but, currently, the status of MGMT should have an
important role in the decision making for patients with
metastatic NENs, in order to plan the best therapeutic
approach.
Funding This research did not receive any specific grant from any
funding agency in the public, commercial or not-for-profit sector.
Compliance with ethical standards
Conflict of interest The authors declare that they have no competing
interests.
Endocrine
Ethical approval All procedures performed in studies involving
human participants were in accordance with the ethical standards of
the institutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical
standards.
Informed consent Informed consent was obtained from all indivi-
dual participants included in the study.
References
1. J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J.E. Mares,
E.K. Abdalla, J.B. Fleming, J.N. Vauthey, A. Rashid, D.B. Evans,
One hundred years after “carcinoid”: epidemiology of and prog-
nostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J. Clin. Oncol. 26(18), 3063–3072 (2008)
2. G. Rindi, G. Kloppel, A. Couvelard, P. Komminoth, M. Korner, J.
M. Lopes, A.M. McNicol, O. Nilsson, A. Perren, A. Scarpa, J.Y.
Scoazec, B. Wiedenmann, TNM staging of midgut and hindgut
(neuro) endocrine tumors: a consensus proposal including a
grading system. Virchows Arch. 451(4), 757–762 (2007)
3. E. Raymond, L. Dahan, J.L. Raoul, Y.J. Bang, I. Borbath, C.
Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, J.S.
Chen, D. Horsch, P. Hammel, B. Wiedenmann, E. Van Cutsem, S.
Patyna, D.R. Lu, C. Blanckmeister, R. Chao, P. Ruszniewski,
Sunitinib malate for the treatment of pancreatic neuroendocrine
tumors. N. Engl. J. Med. 364(6), 501–513 (2011)
4. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, E. Van
Cutsem, T.J. Hobday, T. Okusaka, J. Capdevila, E.G. de Vries, P.
Tomassetti, M.E. Pavel, S. Hoosen, T. Haas, J. Lincy, D. Leb-
wohl, K. Oberg, Rad001 in advanced neuroendocrine tumors, T.T.
S.G.: Everolimus for advanced pancreatic neuroendocrine tumors.
N. Engl. J. Med. 364(6), 514–523 (2011)
5. J.C. Yao, N. Fazio, S. Singh, R. Buzzoni, C. Carnaghi, E. Wolin,
J. Tomasek, M. Raderer, H. Lahner, M. Voi, L.B. Pacaud, N.
Rouyrre, C. Sachs, J.W. Valle, G. Delle Fave, E. Van Cutsem, M.
Tesselaar, Y. Shimada, D.Y. Oh, J. Strosberg, M.H. Kulke, M.E.
Pavel, Everolimus for the treatment of advanced, non-functional
neuroendocrine tumours of the lung or gastrointestinal tract
(RADIANT-4): a randomised, placebo-controlled, phase 3 study.
Lancet 387(10022), 968–977 (2016)
6. L. de Mestier, C. Dromain, G. d’Assignies, J.Y. Scoazec, N.
Lassau, R. Lebtahi, H. Brixi, E. Mitry, R. Guimbaud, F. Courbon,
M. d’Herbomez, G. Cadiot, Evaluating digestive neuroendocrine
tumor progression and therapeutic responses in the era of targeted
therapies: state of the art. Endocr. Relat. Cancer 21(3),
R105–R120 (2014)
7. M.H. Kulke, K. Stuart, P.C. Enzinger, D.P. Ryan, J.W. Clark, A.
Muzikansky, M. Vincitore, A. Michelini, C.S. Fuchs, Phase II
study of temozolomide and thalidomide in patients with metastatic
neuroendocrine tumors. J. Clin. Oncol.: Off. J. Am. Soc. Clin.
Oncol. 24(3), 401–406 (2006)
8. J.R. Strosberg, R.L. Fine, J. Choi, A. Nasir, D. Coppola, D.T.
Chen, J. Helm, L. Kvols, First-line chemotherapy with capecita-
bine and temozolomide in patients with metastatic pancreatic
endocrine carcinomas. Cancer 117(2), 268–275 (2011)
9. J.A. Chan, K. Stuart, C.C. Earle, J.W. Clark, P. Bhargava, R.
Miksad, L. Blaszkowsky, P.C. Enzinger, J.A. Meyerhardt, H.
Zheng, C.S. Fuchs, M.H. Kulke, Prospective study of bev-
acizumab plus temozolomide in patients with advanced neu-
roendocrine tumors. J. Clin. Oncol. 30(24), 2963–2968 (2012)
10. R.L. Fine, A.P. Gulati, B.A. Krantz, R.A. Moss, S. Schreibman,
D.A. Tsushima, K.B. Mowatt, R.D. Dinnen, Y. Mao, P.D.
Stevens, B. Schrope, J. Allendorf, J.A. Lee, W.H. Sherman, J.A.
Chabot, Capecitabine and temozolomide (CAPTEM) for meta-
static, well-differentiated neuroendocrine cancers: The Pancreas
Center at Columbia University experience. Cancer Chemother.
Pharmacol. 71(3), 663–670 (2013)
11. S.L. Gerson, MGMT: its role in cancer aetiology and cancer
therapeutics. Nat. Rev. Cancer 4(4), 296–307 (2004)
12. M.R. Middleton, J.M. Lunn, C. Morris, G. Rustin, S.R. Wedge,
M.H. Brampton, M.J. Lind, S.M. Lee, D.R. Newell, N.M. Blee-
hen, E.S. Newlands, A.H. Calvert, G.P. Margison, N. Thatcher,
O6-methylguanine-DNA methyltransferase in pretreatment
tumour biopsies as a predictor of response to temozolomide in
melanoma. Br. J. Cancer 78(9), 1199–1202 (1998)
13. M.E. Hegi, A.C. Diserens, T. Gorlia, M.F. Hamou, N. de Tribolet,
M. Weller, J.M. Kros, J.A. Hainfellner, W. Mason, L. Mariani, J.
E. Bromberg, P. Hau, R.O. Mirimanoff, J.G. Cairncross, R.C.
Janzer, R. Stupp, MGMT gene silencing and benefit from temo-
zolomide in glioblastoma. N. Engl. J. Med. 352(10), 997–1003
(2005)
14. O.L. Chinot, M. Barrie, S. Fuentes, N. Eudes, S. Lancelot, P.
Metellus, X. Muracciole, D. Braguer, L. Ouafik, P.M. Martin, H.
Dufour, D. Figarella-Branger, Correlation between O6-
methylguanine-DNA methyltransferase and survival in inoper-
able newly diagnosed glioblastoma patients treated with neoad-
juvant temozolomide. J. Clin. Oncol. 25(12), 1470–1475 (2007)
15. S. Ekeblad, A. Sundin, E.T. Janson, S. Welin, D. Granberg, H.
Kindmark, K. Dunder, G. Kozlovacki, H. Orlefors, M. Sigurd, K.
Oberg, B. Eriksson, B. Skogseid, Temozolomide as monotherapy
is effective in treatment of advanced malignant neuroendocrine
tumors. Clin. Cancer Res. 13(10), 2986–2991 (2007)
16. A.M. Schmitt, M. Pavel, T. Rudolph, H. Dawson, A. Blank, P.
Komminoth, E. Vassella, A. Perren, Prognostic and predictive
roles of MGMT protein expression and promoter methylation in
sporadic pancreatic neuroendocrine neoplasms. Neuroendocri-
nology 100(1), 35–44 (2014)
17. T. Walter, B. van Brakel, C. Vercherat, V. Hervieu, J. Forestier, J.
A. Chayvialle, Y. Molin, C. Lombard-Bohas, M.O. Joly, J.Y.
Scoazec, O6-Methylguanine-DNA methyltransferase status in
neuroendocrine tumours: prognostic relevance and association
with response to alkylating agents. Br. J. Cancer 112(3), 523–531
(2015)
18. J. Cros, O. Hentic, V. Rebours, M. Zappa, N. Gille, N. Theou-
Anton, D. Vernerey, F. Maire, P. Levy, P. Bedossa, V. Paradis, P.
Hammel, P. Ruszniewski, A. Couvelard, MGMT expression
predicts response to temozolomide in pancreatic neuroendocrine
tumors. Endocr. Relat. Cancer 23(8), 625–633 (2016)
19. M. Cives, M. Ghayouri, B. Morse, M. Brelsford, M. Black, A.
Rizzo, A. Meeker, J. Strosberg, Analysis of potential response
predictors to capecitabine/temozolomide in metastatic pancreatic
neuroendocrine tumors. Endocr. Relat. Cancer 23(9), 759–767
(2016)
20. M.H. Kulke, J.L. Hornick, C. Frauenhoffer, S. Hooshmand, D.P.
Ryan, P.C. Enzinger, J.A. Meyerhardt, J.W. Clark, K. Stuart, C.S.
Fuchs, M.S. Redston, O6-methylguanine DNA methyltransferase
deficiency and response to temozolomide-based therapy in
patients with neuroendocrine tumors. Clin. Cancer Res. 15(1),
338–345 (2009)
21. G. Rindi, G. Kloppel, H. Alhman, M. Caplin, A. Couvelard, W.W.
de Herder, B. Erikssson, A. Falchetti, M. Falconi, P. Komminoth,
M. Korner, J.M. Lopes, A.M. McNicol, O. Nilsson, A. Perren, A.
Scarpa, J.Y. Scoazec, B. Wiedenmann; all other Frascati Con-
sensus Conference, p., European Neuroendocrine Tumor, S.,
TNM staging of foregut (neuro)endocrine tumors: a consensus
proposal including a grading system. Virchows Arch. 449(4),
395–401 (2006)
Endocrine
22. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S.
Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A.T. van
Oosterom, M.C. Christian, S.G. Gwyther, New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National
Cancer Institute of the United States, National Cancer Institute of
Canada. J. Natl. Cancer Inst. 92(3), 205–216 (2000)
23. S.M. Dong, E.J. Lee, E.S. Jeon, C.K. Park, K.M. Kim, Pro-
gressive methylation during the serrated neoplasia pathway of the
colorectum. Mod. Pathol. 18(2), 170–178 (2005)
24. L. Karayan-Tapon, V. Quillien, J. Guilhot, M. Wager, G. Fro-
mont, S. Saikali, A. Etcheverry, A. Hamlat, D. Loussouarn, L.
Campion, M. Campone, F.M. Vallette, C. Gratas-Rabbia-Re,
Prognostic value of O6-methylguanine-DNA methyltransferase
status in glioblastoma patients, assessed by five different methods.
J. Neurooncol. 97(3), 311–322 (2010)
25. V. Quillien, A. Lavenu, L. Karayan-Tapon, C. Carpentier, M.
Labussiere, T. Lesimple, O. Chinot, M. Wager, J. Honnorat, S.
Saikali, F. Fina, M. Sanson, D. Figarella-Branger, Comparative
assessment of 5 methods (methylation-specific polymerase chain
reaction, MethyLight, pyrosequencing, methylation-sensitive
high-resolution melting, and immunohistochemistry) to analyze
O6-methylguanine-DNA-methyltranferase in a series of 100
glioblastoma patients. Cancer 118(17), 4201–4211 (2012)
26. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J.
Taphoorn, R.C. Janzer, S.K. Ludwin, A. Allgeier, B. Fisher, K.
Belanger, P. Hau, A.A. Brandes, J. Gijtenbeek, C. Marosi, C.J.
Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T.
Gorlia, M. Weller, D. Lacombe, J.G. Cairncross, R.O. Miriman-
off; European Organisation for, R., Treatment of Cancer Brain, T.,
Radiation Oncology, G., National Cancer Institute of Canada
Clinical Trials, G., Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009)
27. C.Y. Hsu, H.L. Ho, S.C. Lin, M.H. Chen, S.P. Hsu, Y.S. Yen, W.
Y. Guo, D.M. Ho, Comparative assessment of four methods to
analyze MGMT status in a series of 121 glioblastoma patients.
Appl. Immunohistochem. Mol. Morphol. 25(7), 497–504 (2017)
28. M. Pavel, D. O’Toole, F. Costa, J. Capdevila, D. Gross, R.
Kianmanesh, E. Krenning, U. Knigge, R. Salazar, U.F. Pape, K.
Oberg; Vienna Consensus Conference, p., ENETS consensus
guidelines update for the management of distant metastatic disease
of intestinal, pancreatic, bronchial neuroendocrine neoplasms
(NEN) and NEN of unknown primary site. Neuroendocrinology
103(2), 172–185 (2016)
29. P. Girot, C. Dumars, J.F. Mosnier, L. Muzellec, H. Senellart, F.
Foubert, F.X. Caroli-Bosc, E. Cauchin, N. Regenet, T. Matysiak-
Budnik, Y. Touchefeu, Evaluation of O6-methylguanine-DNA
methyltransferase as a predicting factor of response to
temozolomide-based chemotherapy in well-differentiated meta-
static pancreatic neuroendocrine tumors. Eur. J. Gastroenterol.
Hepatol. 29(7), 826–830 (2017)
30. N. Raj, D.S. Klimstra, N. Horvat, L. Zhang, J.F. Chou, M.
Capanu, O. Basturk, R.K.G. Do, P.J. Allen, D. Reidy-Lagunes,
O6-Methylguanine DNA methyltransferase status does not predict
response or resistance to alkylating agents in well-differentiated
pancreatic neuroendocrine tumors. Pancreas 46(6), 758–763
(2017)
31. S. Krug, M. Boch, P. Rexin, T.M. Gress, P. Michl, A. Rinke,
Impact of therapy sequence with alkylating agents and MGMT
status in patients with advanced neuroendocrine tumors. Antic-
ancer. Res. 37(5), 2491–2500 (2017)
32. F. Panzuto, E. Merola, M.E. Pavel, A. Rinke, P. Kump, S. Partelli,
M. Rinzivillo, V. Rodriguez-Laval, U.F. Pape, R. Lipp, T. Gress,
B. Wiedenmann, M. Falconi, G. Delle Fave, Stage IV gastro-
entero-pancreatic neuroendocrine neoplasms: A risk score to
predict clinical outcome. Oncologist 22(4), 409–415 (2017)
33. F. Panzuto, L. Boninsegna, N. Fazio, D. Campana, M.P. Brizzi, G.
Capurso, A. Scarpa, F. De Braud, L. Dogliotti, P. Tomassetti, G.
Delle Fave, M. Falconi, Metastatic and locally advanced pan-
creatic endocrine carcinomas: Analysis of factors associated with
disease progression. J. Clin. Oncol. 29(17), 2372–2377 (2011)
34. F. Panzuto, D. Campana, N. Fazio, M.P. Brizzi, L. Boninsegna, F.
Nori, G. Di Meglio, G. Capurso, A. Scarpa, L. Dogliotti, F. De
Braud, P. Tomassetti, G. Delle Fave, M. Falconi, Risk factors for
disease progression in advanced jejunoileal neuroendocrine
tumors. Neuroendocrinology 96(1), 32–40 (2012)
Endocrine
